Michael Richard Dwyer Ashton

SkyePharma Plc engaged in the provision of pharmaceutical business. It involved in development and supply of pharmaceutical products. The company was founded by Ian Roderick Gowrie-Smith on August 18, 1910 and was headquartered in London, the United Kingdom.

Astralis Ltd. research and develop drugs for the treatment of immune system disorders and skin diseases. The company's initial product is Psoraxine, a protein extract used for the treatment of the skin disease psoriasis. Psoraxine is a synthesized immuno-therapeutic agent, presented in liquid form and is packed in 0.5 mg ampules for intra-muscular injection. The company's second product is for the treatment of leishmaniasis. The company was founded on June 30, 2001 and is headquartered in Fairfield, NJ.

Vital Living, Inc. manufactures and markets bionutritionals and nutraceuticals. It develops nutritional products, utilizing drug delivery technologies, including the geomatrix technology through its affiliation with SkyePharma Plc. The company was founded on January 22, 2001 and is headquartered in Boca Raton, FL.

Transition Therapeutics, Inc. develops novel therapeutics for disease indications. It operates through research and development of therapeutic agents segment. The firm's products include ELND005 for the treatment of alzheimer's disease, bipolar disorder and down syndrome. Its metabolic drug candidate is TT401 for treatment of type 2 diabetes and accompanying obesity. Transition Therapeutics was founded by Tony F. Cruz on July 6, 1998 and is headquartered in Toronto, Canada.

LMA International NV engages in the designing, developing, marketing and distributing of medical equipment. It operates in the Anaesthesia and Related Products, and Urology segments. The Anaesthesia and Related Products segment is managed through the subsidiary in the United States, LMA North America, and International, where business is undertaken through the remaining subsidiaries. The Urology segment owns the rights to a lithotripsy device that treats stones. The company was founded by Robert Gaines-Cooper on July 28, 1998 and is headquartered in Willemstad, Netherlands.

Proximagen Group Plc engages in the business of discovery and development of therapeutic treatments. The company was founded by Jenner Peter on November 2003 and is headquartered in Cambridge, the United Kingdom.